Biocon Limited has informed the Exchange regarding Chairperson's Speech at the 47th Annual General Meeting of the Company.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon held its 47th AGM on August 8, 2025, with the Chairperson's speech recapping FY25 performance and strategy. Consolidated revenue grew 5% to ₹164,699 million (USD 1.95 billion), EBITDA rose 5% to ₹43,745 million, and profit for the year stood at ₹10,133 million. Biosimilars led growth at 15%, while Generics and Research Services grew 8% and 4% respectively. Key milestones include the U.S. FDA approval of Biosimilar Insulin Aspart (Kirsty), making Biocon the only company globally with two interchangeable biosimilar insulins in the U.S., and entry into the GLP-1 'diabesity' space with the UK launch of generic Liraglutide. On the capital side, Biocon Biologics raised USD 800 million via Singapore-listed bonds and Biocon Limited raised ₹45 billion through a QIP in June 2025.
The speech reinforces Biocon's leadership in affordable diabetes care and biosimilars, with strong capital raising (QIP + bonds) strengthening the balance sheet for future growth. Shareholders can expect continued investment in GLP-1 and biosimilar pipelines, though no specific margin or earnings guidance was provided.